Anthony Kong
Affiliations: | 2004-2007 | University of Oxford, Oxford, United Kingdom |
Google:
"Anthony Kong"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kong A, Mehanna H. (2021) WEE1 Inhibitor: Clinical Development. Current Oncology Reports. 23: 107 |
| Mumin NH, Drobnitzky N, Patel A, et al. (2019) Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. Bmc Cancer. 19: 102 |
| Garcia Foncillas J, Aftimos PG, Barthelemy P, et al. (2018) Clinical utility of complex multi-platform profiling in metastatic cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii480 |
| Pistilli B, Pluard T, Urruticoechea A, et al. (2017) Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy. Breast Cancer Research and Treatment. 168: 357-364 |
| Gijsen M, King P, Perera T, et al. (2016) Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer. Plos Biology. 14: e1002414 |
| Feldinger K, Kong A. (2015) Profile of neratinib and its potential in the treatment of breast cancer. Breast Cancer (Dove Medical Press). 7: 147-62 |
| Leung WY, Roxanis I, Sheldon H, et al. (2015) Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget. 6: 5678-94 |
| Feldinger K, Kong A. (2015) Profile of neratinib and its potential in the treatment of breast cancer Breast Cancer: Targets and Therapy. 7: 147-162 |
| Mohd Nafi SN, Generali D, Kramer-Marek G, et al. (2014) Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5: 5934-49 |
| Feldinger K, Generali D, Kramer-Marek G, et al. (2014) ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5: 6633-46 |